Abstract OT1-1-12: A phase 3, open-label, randomized, parallel, 2-arm multi-center study of the oral PARP inhibitor BMN 673 versus physician's choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA study)
Year: 2015
Type: conference-abstract
Source: Cancer Research
Institutions: The University of Texas MD Anderson Cancer Center, Texas Oncology, Samsung Medical Center, Hospital General Universitario Gregorio Marañón, Indiana University School of Medicine, Institut universitaire du cancer de Toulouse Oncopole, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, National Cancer Coalition, BioMarin (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1594089650